ArticleJournal of clinical microbiology2004
Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest.
Article in Journal of clinical microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 103 citations in OpenAlex.
- Characterisation of Antifungal Resistance to Azoles in Colombian Isolates of Malassezia spp.Mycoses · 2025Article
- Antifungal properties of carvone and linalool againstCurrent medical mycology · 2024Article
- In vitro sensitivity of Malassezia furfur isolates from HIV-positive and negative patients to antifungal agentsBiomedica : revista del Instituto Nacional de Salud · 2023Article
- ERG11 Gene Variability and Azole Susceptibility in Malassezia pachydermatis.Mycopathologia · 2023Article
- In Vitro Assessment of Azole and Amphotericin B Susceptibilities ofJournal of fungi (Basel, Switzerland) · 2022Article
- Review
- Rare Invasive Yeast Infections in Greek Neonates and Children, a Retrospective 12-Year Study.Journal of fungi (Basel, Switzerland) · 2020Article
- Successful Treatment ofOpen forum infectious diseases · 2020Article
- In Vitro Azole and Amphotericin B Susceptibilities ofAntibiotics (Basel, Switzerland) · 2020Article
- Susceptibilities ofHeliyon · 2020Article
- Review
- Review
- Strain-Specific Metabolic Requirements Revealed by a Defined Minimal Medium for Systems Analyses ofApplied and environmental microbiology · 2019Article
- Antifungal activity of silver nanoparticles in combination with ketoconazole against Malassezia furfur.AMB Express · 2019Article
- Methodological Issues in Antifungal Susceptibility Testing of Malassezia pachydermatis.Journal of fungi (Basel, Switzerland) · 2017Review
- Antifungal Susceptibility Testing of Malassezia spp. with an Optimized Colorimetric Broth Microdilution Method.Journal of clinical microbiology · 2017Article
- Azole Antifungal Sensitivity of Sterol 14α-Demethylase (CYP51) and CYP5218 from Malassezia globosa.Scientific reports · 2016Article
- Global Analysis of the Fungal Microbiome in Cystic Fibrosis Patients Reveals Loss of Function of the Transcriptional Repressor Nrg1 as a Mechanism of Pathogen Adaptation.PLoS pathogens · 2015Article
- Malassezia infections in humans and animals: pathophysiology, detection, and treatment.PLoS pathogens · 2015Review
- Prolonged fever and splenic lesions caused by Malassezia restricta in an immunocompromised patient.Pediatric transplantation · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel formulation of RPMI 1640 medium for susceptibility testing of Malassezia yeasts by broth microdilution (BMD) and Etest is proposed. A modification of the NCCLS M27-A2 BMD method was used to test 53 isolates of Malassezia furfur (12 isolates), M. sympodialis (8 isolates), M. slooffiae (4 isolates), M. globosa (22 isolates), M. obtusa (2 isolates), M. restricta (2 isolates), M. pachydermatis (1 isolates), and M. dermatis (2 isolates) against amphotericin B, ketoconazole, itraconazole, fluconazole, voriconazole, terbinafine, and posaconazole by BMD and Etest. RPMI and antibiotic medium 3 (AM3) were supplemented with glucose, bile salts, a mixture of fatty acids, and n-octadecanoate fatty acids and Tween 20. M. furfur ATCC 14521 and M. globosa ATCC 96807 were used as quality control strains. Depending on the species, MICs were read after 48 or 72 h of incubation at 32 degrees C. Low azole and terbinafine MICs were recorded for all Malassezia species, whereas amphotericin B displayed higher MICs (>/=16 microg/ml) against M. furfur, M. restricta, M. globosa, and M. slooffiae strains, which were AM3 confirmed. Agreement of the two methods was 84 to 97%, and intraclass correlation coefficients were statistically significant (P < 0.001). Because of higher amphotericin B MICs provided by Etest for strains also displaying high BMD MICs (>/=1 microg/ml), agreement was poorer. The proposed media are used for the first time and can support optimum growth of eight Malassezia species for recording concordant BMD and Etest MICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.